Abbott this week introduced the mPlus, a new capability for its RealTime m2000 molecular diagnostics system.
The mPlus capability makes it possible for laboratories of any size to perform molecular diagnostic tests for infectious disease detection and therapy monitoring. Specifically, it will give laboratories the ability to process samples when they are ready rather than holding them for larger batch runs, thus providing faster results to patients. mPlus will also optimize reagent use, reduce laboratory cost of operations, and offer a new automatic inventory feature to improve system and ease of use, Abbott said.
mPlus capability is currently available for Abbott's RealTime HIV, HCV, HBV, CT/NG, and CT assays outside the US and for the RealTime CT/NG assay within the US.